Opendata, web and dolomites

MetaboMARKER

A metabolism-based prognostic biomarker for prostate cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MetaboMARKER project word cloud

Explore the words cloud of the MetaboMARKER project. It provides you a very rough idea of what is the project "MetaboMARKER" about.

potentially    treatments    uncertain    15    funds    exhibit    least    followed    subsequent    escapers    strategy    fail    societies    patent    progress    therapy    tools    differentiate    disease    therapeutic    intensive    pressure    sixth    life    commercialization    affordable    resides    public    predominantly    co    prostate    health    western    line    harbouring    final    treatment    plan    prone    tumour    recurrence    prostatectomy    impose    localised    secondary    castration    decade    guidelines    lack    stg    capacity    efficient    informs    protected    obesity    enrolled    treating    biomarker    therapies    urgently    endangering    men    first    fraction    costly    diagnosis    chemical    cancer    frequently    localized    clinicians    risk    responders    recurrent    sources    metastasize    erc    progressively    lives    prevalent    morbidities    poc    last    age    vs    pc    chemotherapy    exhibited    336343    mortality    employ    resist    cancermetab    prognostic    framework    metabomarker    patients    strategies    radiotherapy    profound   

Project "MetaboMARKER" data sheet

The following table provides information about the project.

Coordinator
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS 

Organization address
address: PARQUE TECNOLOGICO EDIFICIO 801 A
city: DERIO VIZCAYA
postcode: 48160
website: www.cicbiogune.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) coordinator 150˙000.00

Map

 Project objective

Prostate cancer (PC) is the most prevalent tumour type among men. The fraction of patients that exhibit disease recurrence can reach 15% and they face an uncertain future, since this type of tumour is prone to resist to subsequent therapeutic strategies. Current guidelines for treatment of PC include prostatectomy or radiotherapy as first line therapy for localized disease, and chemical castration followed by chemotherapy for recurrent PC. The lack of capacity to identify therapy responders vs. escapers in PC is one of the sources for its important mortality. The challenge resides in providing clinicians with a robust and affordable biomarker that informs about the success of first line therapy in localised PC, and that allows them to employ more intensive therapeutic strategies in high-risk patients. The development of such prognostic tools is urgently needed, since western societies are facing profound changes in the major PC risk factors, including age and obesity. Last, but not least, the cost of treating PC will progressively impose strong pressure in the public health system. In addition, patients that fail first-line therapy can be enrolled in subsequent therapies for up to a decade, and given their advance age (PC predominantly presents in the sixth decade of life) they frequently present endangering and costly co-morbidities and secondary effects. MetaboMARKER, a novel biomarker developed in the framework of the ERC-StG-336343-CancerMetab and already protected under a European patent, is able to differentiate patients harbouring a PC that would progress and potentially metastasize, from those that exhibited a disease that would not likely be a risk to their lives. Thus, MetaboMARKER may contribute to more efficient diagnosis, improved treatments and better distribution of funds in disease management. The aim of the present PoC is to further develop the final biomarker for its commercialization and define the best exploitation strategy plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METABOMARKER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METABOMARKER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DimorphicCircuits (2019)

Elucidating the development of sexually-dimorphic circuits: from molecular mechanisms to synapses and behavior

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  
lastchecktime (2022-08-12 3:36:50) correctly updated